Breezula
Things are really heating up in the hair loss treatment industry on the first day of Summer 2023. Let’s take a look at all pertinent information and happenings in the AGA clinical trial world below. Cosmo Pharma Lists Phase 3 Trial On ClinicalTrials.gov A trial which was once highly anticipated, then questioned if it would…
Read More
Today, Cassiopea SpA has announced topline data from its fully completed phase 2 dose ranging trial for men with androgenic alopecia. The results of the trial were favorable. Phase 2 Trial for Clascoterone The trial which was completed by Cassiopea included 400 men and 4 different doses of clascoterone, also known as breezula, for the…
Read MoreThings are heating up. Cassiopea SpA issued a press release today announcing “very positive” interim analysis phase 2 results for Breezula in the treatment of androgenic alopecia. Breezula is a topical anti-androgen and also known as Clascoterone. Here are some significant details I found while reading the release: The trial comprises 404 subjects and is…
Read More